51st Annual Meeting of the EBMT congress coverage: Lymphoma (Part 1)

Catch up with our live social media coverage of lymphoma from the 51st Annual Meeting of the EBMT.

Pirtobrutinib receives positive CHMP opinion for the treatment of adult patients with R/R CLL and previous BTKi exposure

On February 28, 2025, the EMA CHMP issued a positive opinion and recommendation...

ZUMA-5: 5-year follow-up analysis of axicabtagene ciloleucel in patients with R/R iNHL

We summarize 5-year follow-up results from the phase II ZUMA-5 trial evaluating the safety and efficacy of...

MITHIC-FL1: Mosunetuzumab monotherapy in newly diagnosed follicular lymphoma

We summarize primary analysis results from the phase II MITHIC LF-1 trial evaluating the safety and efficacy of...

Orelabrutinib receives China’s National Medical Products Administration approval for adult patients with previously untreated CLL/SLL

Orelabrutinib has received China’s NMPA approval for patients...

Talicabtagene autoleucel for patients with R/R B-cell malignancies: Results from a phase I/II trial

We summarize results from a phase I/II trial assessing the safety and efficacy of talicabtagene...

European Commission approves glofitamab in combination with gemcitabine and oxaliplatin for the treatment of adult patients with R/R DLBCL

The EC has approved glofitamab in combination with...

POLARIX subgroup analysis: Pola-R-CHP for older patients aged ≥60 years with untreated DLBCL

We summarize key results from a subgroup analysis of the phase III POLARIX trial evaluating the safety and...

IRENE-G: A prospective RCT of nutritional support following allo-HSCT

The Lymphoma Hub is pleased to summarize the design and rationale of the IRENE-G trial (NCT05111834; Impact of Resistance Exercise...

What supportive care is needed for patients receiving CAR T-cell therapy?

During the 4th European CAR T-cell Meeting, the Lymphoma Hub was pleased to speak with Natacha Bolaños, Lymphoma Coalition,...

Axi-cel vs chemoimmunotherapy in older patients with R/R LBCL

Here, we summarize results from an analysis comparing real-world outcomes of axicabtagene ciloleucel vs chemoimmunotherapy in patients...

How to treat older and frail patients with CLL?

During the Lymphoma Hub Steering Committee in October 2023, members discussed how to treat older and frail patients with CLL.

How can we improve care for elderly patients with HL?

During the Society of Hematologic Oncology (SOHO) 2023 Congress, the Lymphoma Hub spoke to Jonathan Friedberg, James P. Wilmot Cancer Centre, New...

POLARIX trial: Is Pola-R-CHP effective and safe in elderly patients with DLBCL?

During the 17th ICML, the Lymphoma Hub spoke to Hervé Tilly, Centre Henri-Becquerel and University of Rouen, Rouen, FR....